Celldex (CLDX) jumps 9.6% after saying its CDX-011 drug delayed tumor growth and extended the...

|About: Celldex Therapeutics, Inc (CLDX)|By:, SA News Editor

Celldex (CLDX) jumps 9.6% after saying its CDX-011 drug delayed tumor growth and extended the survival of patients with advanced breast cancer compared with those who received single-agent chemotherapy in a Phase II trial. Seattle Genetics (SGEN) also has an interest in the drug. Celldex now hopes to persuade the FDA to authorize a confirmatory study of CDX-011, which could lead to accelerated approval. (PR)